Navigation Links
Merz Pharmaceuticals' Belotero(R) Balance PMA Filing Formally Accepted for Review by the FDA
Date:9/11/2009

GREENSBORO, N.C., Sept. 11 /PRNewswire/ -- Merz Pharmaceuticals, LLC, a leading specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Merz's premarket approval (PMA) application for Belotero(R) Balance.

Belotero(R) Balance is a hyaluronic acid based monophasic gel dermal filler that utilizes a cohesive polydensified matrix (CPM(TM)) technology. This application seeks FDA approval for injection into mid-to-deep dermis for correction of moderate to severe wrinkles and folds.

"The FDA's acceptance for review of the Belotero(R) Balance PMA begins the application review process and signifies the beginning of Merz Pharmaceutical's firm footprint in the American aesthetics market," said Jack Britts, president and CEO of Merz Pharmaceuticals, LLC.

"Upon approval, Belotero(R) Balance will be an exciting addition to the dermal filler category," said Dr. Rhoda S. Narins, M.D., the lead investigator for the Belotero(R) clinical trials.

About Belotero(R)

First launched in Germany in 2005, Belotero(R) is also approved for aesthetic use in the United Kingdom, Italy, Russia, Austria and Switzerland.

About Merz Pharmaceuticals

Merz Pharmaceuticals, LLC, a wholly owned, U.S. subsidiary of the Merz Group of Companies was established in 1995 and develops and commercializes prescription products for Neurology, Dermatology, Podiatry and the #1 non-prescription product for scars, Mederma.

With a 101 year heritage, Merz (KGaA) is known worldwide for its development of original compounds and formulations for medical professionals and consumers in 90 countries. Globally, Merz is a leader in the development of pharmaceuticals for the treatment of neurological and psychological disorders as well as for aesthetic medicine, including products for the treatment of wrinkles and aging skin, hair loss and acne. Research is concentrated in fields that have a strong need for therapeutic innovation such as Alzheimer's disease, Parkinson's disease, tinnitus, chronic pain conditions, addictions, and neuromuscular disturbances.


'/>"/>
SOURCE Merz Pharmaceuticals, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Access Pharmaceuticals Signs Agreement to Manufacture Its FDA-Approved MuGard in the United States
2. Amylin Pharmaceuticals and Biocon Limited Enter a Global Development and Commercialization Agreement for a Novel Peptide Hybrid
3. Ritter Pharmaceuticals Hires Dr. Howard Foyt as Executive Vice President, Development & Chief Medical Officer
4. Reportlinker Adds US and European Radiopharmaceuticals Market Report
5. Cumberland Pharmaceuticals Launches Caldolor(R) in the United States for Treatment of Pain and Fever
6. Isis Pharmaceuticals to Present at Morgan Stanleys Global Healthcare Unplugged Conference
7. Rib-X Pharmaceuticals, Inc. Appoints Tom Kassberg Chief Business Officer
8. Jazz Pharmaceuticals to Present at Two Upcoming Investor Conferences
9. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
10. Amira Pharmaceuticals to Present at Thomas Weisel Partners Healthcare Conference
11. Steven Holtzman Joins Satori Pharmaceuticals Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... March 29, 2017 , ... ... scientific laboratories. The assembly protocols involve many repetitive steps and often scientists require ... which enables the high-throughput needed, and results in a lower error rate and ...
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... ... of Gastrointestinal Oncology™ (SOGO™), a specialized continuing medical education conference for clinicians who ... at Intercontinental Time Square, New York. , The program will be led ...
(Date:3/28/2017)... ... March 28, 2017 , ... A recent Bellwether Education ... quality, the field must first improve teacher preparation program design. It then asserts ... and that decades of input- and outcome-based research has failed to improve teacher ...
(Date:3/28/2017)... ... March 28, 2017 , ... Greenfield Advisors ... brings his extensive knowledge of appraisals, property values, ad valorem taxation, and government ... valuation industry for more than 40 years. , “Ruel is a great addition ...
(Date:3/28/2017)... ... 2017 , ... Dr. Isabella Wentz, PharmD, FASCP, one of the leading thyroid ... Thyroid Secret. Dr. Wentz talked about journey and research recently on a blog and ... NOT the only solution to deal with thyroid disease. , Dr. Wentz completed ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... USA, March 29, 2017 Stryker announced today ... by People magazine, in partnership with Great Place to ... on the list. This list highlights the top U.S. ... in business while also demonstrating respect, compassion and concern ... To determine the companies on the list, ...
(Date:3/29/2017)... FinancialBuzz.com News Commentary  ... Data published in a research report by Grand View Research, ... of USD 55.8 billion by 2025. The projection takes into consideration the ... and a more open approach towards cannabis products around the world. In ... , North Dakota , Ohio , ...
(Date:3/29/2017)... , Mar. 29, 2017 Research and ... and Risk Management Software Market Outlook: 2016-2022" report to their ... The ... by product, mode of delivery, end-user, and geography. ... systems across the globe. The field has developed significantly in the ...
Breaking Medicine Technology: